BioHarvest Sciences Inc. Common Stock (BHST) 股票分析

公司概述

BioHarvest Sciences Inc. operates as a biotechnology entity based in Israel and the United States, utilizing a proprietary botanical synthesis platform technology to produce plant cells characterized by higher concentrations of active ingredients for the Nutraceuticals and Pharmaceuticals segments. The company is categorized within the Consumer Defensive sector and specifically functions in the Packaged Foods industry, which implies its products are essential consumer goods that often exhibit lower price elasticity compared to discretionary spending sectors. As of the latest data, the firm maintains a market capitalization of $97.02 million and employs a workforce of 89 individuals to generate an annual revenue of $34.51 million. These valuation and revenue figures indicate that BioHarvest Sciences Inc. holds a position as a small-cap enterprise with limited market penetration relative to large-cap peers, yet it possesses a specialized technological niche within the broader consumer defensive landscape.

财务健康

The company reported a trailing twelve-month revenue of $34.51 million alongside a net income loss of $11,135,000 and an EBITDA of -$5,111,000, revealing a significant gap where operating costs and expenses substantially exceed gross profits. This disparity between positive revenue and negative net income highlights a cost structure dominated by high operating expenditures, including research and development or administrative overheads that have not yet been offset by profitability. Free cash flow stands at -$10,782,250, indicating that the company is currently burning cash, which limits its immediate financial flexibility and ability to fund operations or acquisitions without external capital. In terms of profitability margins, the gross margin is 59.3%, suggesting efficient production costs relative to sales, while the operating margin is -12.4% and the profit margin is -32.3%, reflecting the heavy burden of operating expenses and the resulting unprofitability at the bottom line. The balance sheet shows a cash position of $23.04 million against total debt of $14.10 million, resulting in a debt-to-equity ratio of 55.42, which suggests a leveraged capital structure given the high equity multiple despite the absolute debt amount being lower than cash reserves. Short-term liquidity appears robust with a current ratio of 3.97, indicating that the company holds nearly four times the current assets required to cover its current liabilities without immediate distress. However, the return on equity is -83.2% and the return on assets is -9.6%, metrics that reveal management has yet to generate positive returns on the capital invested, signaling challenges in translating operational activities into value creation for shareholders.

估值评估

The trailing twelve-month P/E ratio is listed as N/A due to the net loss, while the forward P/E is reported as -107.00, a negative figure that implies earnings are currently negative and the market is pricing in future earnings recovery rather than current profitability. The price-to-book ratio stands at 3.81, indicating that the market values the company at a significant premium of 3.81 times its tangible book value, which often reflects high growth expectations or intangible asset valuations despite current losses. Alternative valuation metrics such as the price-to-sales ratio of 2.81 and the EV/EBITDA of -17.23 further illustrate that the stock is priced based on sales potential rather than earnings generation, as the negative EV/EBITDA confirms the lack of earnings power in the current period. The stock has traded between a 52-week high of $12.80 and a 52-week low of $4.10, and without a specific current price listed in the provided facts, the valuation range indicates substantial volatility with a potential swing of nearly 213% between the annual extremes. The beta value of 1.40 signifies that the stock exhibits 40% higher volatility than the broader market, meaning price movements will be amplified relative to general market trends during periods of instability.

Growth & Income

Revenue growth for the year-over-year period is 24.6%, demonstrating a strong expansion in top-line sales, whereas earnings growth is N/A because the company is currently unprofitable, implying that revenue expansion is not yet translating into bottom-line gains. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm reinvests all available cash flow into operational growth, R&D, or balance sheet strengthening rather than distributing income to shareholders. Consequently, the overall growth and income profile is characterized by aggressive revenue expansion in a defensive sector but a total absence of current income generation or shareholder distributions. The absence of a payout ratio and the significant negative net income confirm that the primary strategy relies on capital appreciation and future profitability rather than current cash yield.